# Remaxol® in Malignant Mechanical Jaundice

> **NCT03416062** · PHASE3 · COMPLETED · sponsor: **POLYSAN Scientific & Technological Pharmaceutical Company** · enrollment: 240 (actual)

## Conditions studied

- Jaundice; Malignant

## Interventions

- **DRUG:** Remaxol®
- **DRUG:** Ringer's Solution

## Key facts

- **NCT ID:** NCT03416062
- **Lead sponsor:** POLYSAN Scientific & Technological Pharmaceutical Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-03
- **Primary completion:** 2020-02-03
- **Final completion:** 2020-03-04
- **Target enrollment:** 240 (ACTUAL)
- **Last updated:** 2020-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03416062

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03416062, "Remaxol® in Malignant Mechanical Jaundice". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03416062. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*